Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Momenta Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (975)	4/18/2007 8:05:13 PM
From: DewDiligence_on_SI	Read Replies (1) \| Respond to of 3027

I think if [TEVA] got a flat "no" they would likely disclose that in their 10K. TEVA files Form 20-F rather than a 10K; the next one (for 2007) won’t be filed until early 2008. If TEVA’s generic Lovenox is approved by then, it may be mentioned in the 20F; if rejected or still pending, it will almost certainly not be mentioned. If they didn't disclose, then insiders would perhaps be barred from trading (other than via a 10b-5 plan). TEVA’s insiders are not bound by SEC insider-trading rules. Regards, Dew